Guardant Health reports preliminary 2023 revenue ~$562-563M (+25% YoY); clinical test volumes up 39%

Guardant Health, Inc.

2023-FY EPS reported -$4.28 revenue$563,948,000

Full year 2023 revenue $562-563M, up 25% YoY; clinical test volume 172,900 (+39%).
Q4 2023 revenue $153-154M (+21%); clinical tests 46,400 (+29%).
Full year free cash flow approx. -$347M; cash and equivalents $1.2B as of Dec 31, 2023.
Co-CEOs cite Shield blood test progress; expect FDA approval and IVD launch in 2024.
Results are preliminary and unaudited; final audited results expected in February 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Guardant Health, Inc. reported the twelve-month period ended December 31, 2023 results: revenue $562 million and $563 million.

Period: the twelve-month period ended December 31, 2023
Revenue: $562 million and $563 million
Result: preliminary results

Exact text from the filing

Full year 2023 preliminary unaudited financial results For the twelve-month period ended December 31, 2023, as compared to the same period of 2022: • Revenue of between $562 million and $563 million, an increase of 25%

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Guardant Health, Inc. reported the three-month period ended December 31, 2023 results: revenue $153 million and $154 million.

Period: the three-month period ended December 31, 2023
Revenue: $153 million and $154 million
Result: preliminary results

Exact text from the filing

Fourth quarter 2023 preliminary unaudited financial results For the three-month period ended December 31, 2023, as compared to the same period of 2022: • Revenue of between $153 million and $154 million, an increase of 21%

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-004446

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.